What is HERG screening?

HERG screening refers to the process of assessing the Human Ether-a-go-go-Related Gene (HERG) for abnormalities or mutations. This gene is associated with cardiac ion channels and is crucial in evaluating potential risks of drug-induced arrhythmias, particularly torsades de pointes.

How big is the HERG Screening Market?

The global HERG Screening Market size was estimated at USD 1,938.0 Million in 2023 and is expected to reach USD 6578.7 Million in 2033.

What is the HERG ScreeningMarket growth?

The global HERG Screening Market is expected to grow at a compound annual growth rate of 13.04%. From 2024 To 2033

Who are the key companies/players in the HERG Screening Market?

Some of the key players in the HERG ScreeningMarkets are AVIVA Biosciences, Axxam, ABCAM plc, AstraZeneca plc, Aureus Sciences, Caliper Discovery Alliances and services, Charles River Laboratories, Creative Bio array, Cerep, ChanTest, Cyprotex Limited, Eurofins Scientific.

Why is HERG screening important?

HERG screening plays a vital role in drug development and safety evaluation by identifying compounds that may prolong the QT interval, a risk factor for life-threatening arrhythmias. It helps pharmaceutical companies assess the cardiac safety profile of new drugs and mitigate the risk of adverse effects.

What are the key market drivers for HERG screening?

The increasing focus on drug safety, stringent regulatory requirements, and growing demand for personalized medicine are key drivers fueling the growth of the HERG screening market. Additionally, advancements in technology, such as high-throughput screening methods and automated platforms, are enhancing efficiency and accuracy in HERG screening processes.

What are the future prospects for the HERG screening market?

The HERG screening market is expected to witness robust growth, driven by increasing pharmaceutical research and development activities, rising awareness about drug-induced cardiac arrhythmias, and the expanding application of HERG screening in drug safety assessment. Technological advancements and collaborations between pharmaceutical companies and research institutions are likely to further propel market growth.

Global HERG Screening Market by Type (Gene KCNH2, Mutant KCNH2), By ION Channel (Voltage-Gated Ion Channel, Ligand-Gated Ion Channel, mechanosensitive, Transient receptor potential), By Application (Antiarrhythmic, Antipsychotic, Antibiotic, Antimalarial, Antihistamine) By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2024-2033

Published date: March 2024
Report ID: 83472
Number of Pages: 320
Format:

- AVIVA Biosciences
- Axxam
- ABCAM plc
- AstraZeneca Plc Company Profile
- Aureus Sciences
- Caliper Discovery Alliances and services
- Charles River Laboratories
- Creative Bio array
- Cerep
- ChanTest
- Cyprotex limited
- Eurofins Scientific
Settings

Related Reports

Our Clients

Inquiry Before Buying

Report ID 83472
Published Date March 2024
Rating
- ★★★★★
  
  ★★★★★
- (82)

Buy Now

Trusted by more than 17382 organizations globally

✖

Request a Sample Report

We'll get back to you as quickly as possible

	Single User $6,000 $3,999 USD / per unit save 24%	Multi User $8,000 $5,999 USD / per unit save 28%	Corporate User $10,000 $6,999 USD / per unit save 32%
e-Access
Report Library Access
Data Set (Excel)
Print
Company Profile Library Access
Interactive Dashboard
Free Custumization	No	up to 10 hrs work	up to 30 hrs work
Accessibility	1 User	2-5 User	Unlimited
Analyst Support	up to 20 hrs	up to 40 hrs	up to 50 hrs
Benefit	Up to 20% off on next purchase	Up to 25% off on next purchase	Up to 30% off on next purchase
	Buy Now ($ 3,999)	Buy Now ($ 5,999)	Buy Now ($ 6,999)